메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP…

Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments SEOUL, South Korea, Jan. 28, 2026 -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease treatment. Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced on January 28 that it has signed an exclusive distribution agreement with Mexican pharmaceutical company Laboratorios Sanfer for efpeglenatide, its GLP-1 obesity the
- 김갑성 기자
- 2026-01-28 12:08
US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Mana…

[ 메디채널 김갑성 기자 ] The US Food and Drug Administration (FDA) has approved Novo Nordisk's new once-daily pill for weight management, designed to help people reduce excess body weight and maintain weight reduction over the long term. In clinical trials, patients achieved an average weight reduction of 16.6% from baseline. The therapy is also indicated to lower the risk of major cardiovascular events* such as heart attack and stroke in certain patients. Novo Nordisk expects to launch the pill in the United States in early January 2026. JAKARTA, Indonesia, Jan. 28, 2026 -- [ 메디채널 김갑성 기자 ]
- 김갑성 기자
- 2026-01-28 10:45
Singapore Eye Research Institute tops ScholarGPS rankings…

The Institute has placed #1 in ophthalmology among all non-academic institutes, and #2 in the same field among all institutes, globally. SINGAPORE, Jan. 28, 2026 -- The Singapore Eye Research Institute (SERI) has achieved a landmark milestone in December 2025 by securing first place among all non-academic institutes in ophthalmology, on the American scholarly analytics platform ScholarGPS, whilst also claiming second place overall among all institutes in the field globally. This is based on data from the last five years evaluated by the platform. The a
- 김갑성 기자
- 2026-01-28 10:00
Organizations Without AI Security Policies Are Already Behind,…

Armor releases AI governance framework to address critical policy gap as enterprise AI adoption accelerates DALLAS, Jan. 28, 2026 -- Armor, a leading provider of cloud-native managed detection and response (MDR) services protecting more than 1,700 organizations across 40 countries, today issued guidance to enterprises: Organizations deploying artificial intelligence tools without formal governance policies are creating avoidable blind spots in their security posture and exposing themselves to data loss, compliance violations, and emerging AI-specific threats. "If yo
- 김갑성 기자
- 2026-01-28 02:21
Asthma and Allergy Drug Development Is Failing Too Often--A T…

BOSTON and SUZHOU, China, Jan. 27, 2026 -- HKeyBio, a preclinical CRO focused on autoimmune and allergic disease drug development, today announced a translational preclinical strategy, HKEY-AIRxTM1.0 designed to address one of the most persistent problems facing biotech leadership: why so many asthma and allergy programs with strong preclinical data fail to deliver meaningful clinical outcomes. Over the past decade, asthma and allergic airway diseases have attracted substantial investment, the emergence of advanced biologics, and increasingly sophisticated targets. Yet for biotech and
- 김갑성 기자
- 2026-01-27 22:00
Insilico Medicine and Qilu Pharmaceutical Reach Near $120…

CAMBRIDGE, Mass., Jan. 27, 2026 -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innovative drug development, leveraging Insilico's proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management. According to the agreement, Insilico Medicine will utilize its pr
- 김갑성 기자
- 2026-01-27 22:00
Home Control Signs Memorandum of Understanding with NTU…

HONG KONG, Jan. 27, 2026 -- Home Control International Limited ("Home Control" or the "Company", together with its subsidiaries, the "Group"; Stock Code: 1747.HK) is pleased to announce that it has entered into a Strategic Memorandum of Understanding (MoU) with Nanyang Technological University, Singapore ("NTU Singapore"). The parties will negotiate and explore the possibility of cooperation and collaboration on Artificial Intelligence of Things ("AIoT") enabled home healthcare solutions, marking a significant milestone in the Group's strategi
- 김갑성 기자
- 2026-01-27 21:25
Skyhawk Therapeutics Announces Nine Month Interim Resu…

Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural history expected worsening of cUHDRS in symptomatic patients of -0.73 points over nine months, based on propensity score weighting. Skyhawk also announces SKY-0515's Phase 2/3 FALCON-HD trial has expanded worldwide. Skyhawk has now dosed more than 90 patients. BOSTON, Jan. 27, 2026 -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA targets,
- 김갑성 기자
- 2026-01-27 21:00
Kazia Therapeutics Reports Encouraging Preliminary Clinic…

SYDNEY, Jan. 27, 2026 -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC). To date, three patients with metastatic TNBC treated with paxalisib-based regimens have demonstrated meaningful clinical responses, including two partial responses (PRs) in trial participants and one confirmed complete metabolic response (CR) in a patient treated under an expanded access program. C
- 김갑성 기자
- 2026-01-27 21:00
스카이호크 테라퓨틱스, 헌팅턴병 치료제 SKY-0515 제1상 임상시험 환자 대상 9개월 중간…

9개월 분석 결과 복합 통합 헌팅턴병 등급 척도가 기저치 대비 평균 0.64점 개선-성향 점수 가중치 적용 시 증상 발현 환자의 9개월 예상 자연 경과 악화 수치인 -0.73점 대비 스카이호크, SKY-0515의 임상 2/3상인 FALCON-HD 시험을 전 세계로 확대한다고 발표- 현재까지 90명 이상의 환자에게 투약 시행 보스턴, 2026년 1월 27일 -- 중요한 RNA 표적을 조절하는 혁신적 저분자 치료제를 개발 중인 임상 단계 바이오테크 기업 스카이호크 테라퓨틱스(Skyhawk Therapeutics, Inc.)가 1월 27일 자사의 헌팅턴병(Huntington's disease, HD) 임상시험 치료제인 SKY-0515의 9개월 중간 분석에서 긍정적인 결과가 도출됐다고 발표했다. SKY-0515 투여 결과 9mg 용량에서 혈액 내 변이 헌팅틴 단백질(mHTT)이 62% 감소하는 등 용량 의존적 감소가 나타났으며, 체세포 CAG 반복 확장 및 헌팅턴병 병리학의 핵심 동인인 PMS1 mRNA는 26% 감소했다. 또한 SKY-0515는 우수한 중추신경계 노출을 입증했으며 전반적으로 안전하
- 김갑성 기자
- 2026-01-27 21:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-31_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 31일 13시 40분